| Code | CSB-RA006163MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Botensilimab, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4). CTLA4 functions as a critical immune checkpoint receptor expressed on T cells, where it competes with the costimulatory receptor CD28 for binding to B7 ligands on antigen-presenting cells. By delivering inhibitory signals, CTLA4 downregulates T-cell activation and maintains immune homeostasis. Dysregulation of CTLA4-mediated signaling is implicated in various cancers that exploit this pathway to evade immune surveillance, as well as in autoimmune disorders where checkpoint function may be compromised.
Botensilimab represents a next-generation CTLA4-targeting antibody with an engineered Fc region designed to enhance intratumoral regulatory T-cell depletion while minimizing systemic immune-related adverse effects. This biosimilar provides researchers with a valuable tool for investigating CTLA4 biology, exploring immune checkpoint mechanisms, and studying combination immunotherapy strategies in preclinical models. It supports investigations into T-cell regulation, tumor immunology, and the development of novel cancer immunotherapeutic approaches.
There are currently no reviews for this product.